奎硫平治疗首发精神分裂症对照研究  

A study of quetiapine in the treatment of first-onset schizophrenia

作　　者：高诚忠[1] 高至胜[1] 龙浩文[1] 

机构地区：[1]湖南省脑科医院,长沙410007

出　　处：《临床精神医学杂志》2003年第4期221-222,共2页Journal of Clinical Psychiatry

摘　　要：目的 :对比奎硫平与氯氮平治疗首发精神分裂症的疗效和安全性。　方法 :分别以奎硫平与氯氮平治疗首发精神分裂症各 30例 ,采用阳性症状与阴性症状量表 (PANSS)、副反应量表 (TESS) ,在治疗前及治疗后第 1、2、4、6、8周末分别评定疗效及不良反应。　结果 :奎硫平有效率 86 7% ,显效率76 7% ;氯氮平有效率 80 0 % ,显效率 6 6 7%。两组治疗后与治疗前的PANSS评分比较差异有显著性性 ,奎硫平不良反应少于氯氮平。　结论 :奎硫平治疗精神分裂症疗效好 ,不良反应较氯氮平轻微 。Objective:To compare the efficacy and safety between quetiapine and clozapine. Method:Thirty schizophrenic patients were treated with quetiapine and another thirty patients treated with clozapine. The efficacy was measured with the positive and negative symptoms scale (PANSS),while the side effects were determined by the treatment emergent symptom scale(TESS). Results:The efficacy rate of quetiapine was 86.7%,in which 76.7% were improved markedly.The efficacy rate of clozapine was 80 0%,in which 66.7% were improved markedly.The PANSS scores in both groups decreased significantly after treatment.Quetiapine has less side effects than clozapine. Conclusion:Quetiapine is of good efficacy, high safety and less side effects in treating schizophrenia, and patients had better compliance.

关 键 词：奎硫平 氯氮平 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]